This article is freely available to all

Article Abstract

‘ ‹’ ‹

Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.

Recent research has indicated a role for antidepressants in such diverse disorders as premenstrual dysphoric disorder, attention-deficit/hyperactivity disorder (ADHD), social phobia, obsessive-compulsive disorder (OCD), borderline personality disorder, and panic disorder. Since the newer serotonin selective reuptake inhibitors (SSRIs), venlafaxine, and nefazodone have a more benign side effect profile than the older tricyclics and monoamine oxidase inhibitors (MAOIs), controlled trials of the newer agents in many different disorders are under way. Preliminary evidence on efficacy, which ranges from randomized controlled trials that point strongly to efficacy to open-label studies with more tentative results, will be presented in this Supplement to The Journal of Clinical Psychiatry.’ ‹